SEC
TPTX

Seven Eight Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Seven Eight Capital’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,049
Closed -$335K – 733
2021
Q3 		$335K Sell
5,049
-801
-14% -$57.1K 0.03% 486
2021
Q2 		$456K Buy
+5,850
New +$432K 0.06% 435

Other funds holding TPTX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Seven Eight Capital's TPTX Position: Q4 2021 in Review

Seven Eight Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 5,049 shares — an estimated $335K sold.

Seven Eight Capital first reported a position in TPTX in Q2 2021 and held it in 2 quarters. The position peaked at $456K in Q2 2021. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

  • Seven Eight Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Seven Eight Capital sold 5,049 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $335K.
  • Seven Eight Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Seven Eight Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $456K in Q2 2021.
  • 172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Seven Eight Capital's 13F filing for Q4 2021, filed 14 Feb 2022.